Citigroup Inc Aclaris Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 12,335 shares of ACRS stock, worth $12,705. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,335

Previous 507,508 97.57%

Holding current value

$12,705

Previous $532,000 97.18%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.92 - $1.44 $455,559 - $713,049	-495,173 Reduced 97.57%	12,335 $15,000
Q4 2023 Feb 09, 2024	BUY	$0.64 - $6.49 $317,212 - $3.22 Million	495,644 Added 4177.71%	507,508 $532,000
Q3 2023 Nov 09, 2023	SELL	$6.56 - $10.95 $119,477 - $199,432	-18,213 Reduced 60.55%	11,864 $81,000
Q2 2023 Aug 10, 2023	SELL	$7.89 - $10.64 $366,608 - $494,387	-46,465 Reduced 60.71%	30,077 $311,000
Q1 2023 May 11, 2023	BUY	$7.07 - $17.95 $411,869 - $1.05 Million	58,256 Added 318.58%	76,542 $619,000

Q4 2022 Feb 09, 2023	BUY	$14.33 - $18.37 $143,342 - $183,755	10,003 Added 120.77%	18,286 $288,000
Q3 2022 Nov 10, 2022	SELL	$13.07 - $18.22 $67,388 - $93,942	-5,156 Reduced 38.37%	8,283 $130,000
Q2 2022 Aug 10, 2022	BUY	$10.16 - $17.08 $51,277 - $86,202	5,047 Added 60.14%	13,439 $187,000
Q1 2022 May 12, 2022	SELL	$9.74 - $17.92 $89,598 - $164,846	-9,199 Reduced 52.29%	8,392 $145,000
Q4 2021 Feb 10, 2022	SELL	$12.27 - $18.49 $82,847 - $124,844	-6,752 Reduced 27.74%	17,591 $256,000
Q3 2021 Nov 10, 2021	BUY	$13.38 - $18.8 $325,709 - $457,648	24,343 New	24,343 $438,000

Others Institutions Holding ACRS

# of Institutions

102

Shares Held

53.5M

Call Options Held

51K

Put Options Held

31.6K

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $68.7M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account